1BSL01AE — Biotika as Income Statement
0.000.00%
- €5.39m
- €3.86m
- €12.15m
Annual income statement for Biotika as, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 17.6 | 8.91 | 11 | 16.2 | 12.2 |
| Cost of Revenue | |||||
| Gross Profit | 9.91 | 7.03 | 5.74 | 7.97 | 5.9 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 15.5 | 8.44 | 12.1 | 16 | 15.5 |
| Operating Profit | 2.16 | 0.472 | -1.08 | 0.163 | -3.34 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 2.73 | 0.515 | -0.843 | 0.221 | -2.83 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2.28 | 0.406 | -0.82 | 0.369 | -2.39 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 2.28 | 0.406 | -0.82 | 0.369 | -2.39 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2.28 | 0.406 | -0.82 | 0.369 | -2.39 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3.23 | 0.576 | -1.19 | 0.447 | -3.55 |
| Dividends per Share |